David Mongeau, now the Founding Director of the School of Data Science at the University of Texas at San Antonio, was the Executive Director of BIDS from April 2018 to June 2021. During that time, in collaboration with the Faculty Director and Faculty Council, he set strategic direction and oversaw the BIDS research, training, and outreach. He also led the institute’s industry and foundation relations and its engagement with other UC and global research institutes, all toward the overarching mission at BIDS to create and deploy data science methods, practices, and technologies to enable discovery. Previously, David co-led the data analytics institute at Ohio State; worked at Battelle, where he championed its proposal for an AI and cybersecurity company, now Covail; and worked for many years at Bell Labs – starting on the team that introduced the first C++ compiler and UNIX System V and leaving after building a global business and technology consulting practice, now part of Nokia Bell Labs Consulting. David earned his undergraduate degree at Carnegie Mellon University, and later earned a graduate degree at Rensselaer Polytechnic Institute and an MBA from Purdue University. Many of his interests lie beyond data science, embracing the humanities and arts.
Chris Kennedy is an instructor in psychiatry at Harvard Medical School / Massachusetts General Hospital. He has a PhD in biostatistics from UC Berkeley. He is a senior fellow at UC Berkeley’s D-Lab and is affiliated with the Integrative Cancer Research Group and the Division of Research at Kaiser Permanente Northern California. At BIDS, he was a BIDS - Biomedical Big Data Training (BBDT) Data Science Fellow and a PhD student in biostatistics at UC Berkeley, where he worked with Alan Hubbard. He was also a D-Lab instructor and consultant, and an NIH biomedical big data trainee. His methodological interests encompassed targeted machine learning, randomized trials, causal inference, deep learning, text analysis, signal processing, and computer vision. His applications were primarily in precision medicine, public health, genomics, and election campaigns. His software projects included the SuperLearner ensemble learning system and varImpact for variable importance estimation; he leverages high performance computing on Savio and XSEDE clusters to accelerate his work. Prior to Berkeley he worked in political analytics in DC, running dozens of randomized trials and integrating machine learning into multi-million dollar programs to improve voter turnout for underrepresented Americans. He has also worked to support climate change action through Al Gore’s Climate Reality Project and the Yale Program on Climate Change Communication. He holds an M.A. in political science from UC Berkeley, an M.P.Aff. from the LBJ School of Public Affairs, and a B.A. in government & economics from The University of Texas at Austin.
Maryam Vareth leads BIDS’ data science research efforts in the Health & Life Sciences. Dr. Vareth is a Co-Director of the Innovate For Health initiative, a collaboration among UC Berkeley, UCSF, and Janssen Pharmaceutical Companies of Johnson & Johnson. As an experienced engineer, researcher, and data scientist, she applies mathematics, statistics and physics to solve unmet needs in healthcare to enhance patients’ experience during their medical journey. She is an advocate for “data-driven” medicine, and in particular for linking medical imaging data with medical diagnostics and therapeutics to extract clinically-relevant insights through the use of open research and open source practices. Dr. Vareth received her BS and MS training in Electrical Engineering and Computer Science (EECS) from UC Berkeley, where she was awarded the prestigious Regent’s and Chancellor’s Scholarship. She completed her PhD through the joint UC Berkeley-UCSF Bioengineering program as a National Science Foundation Fellow, where she was awarded the Margaret Hart Surbeck Endowed Fellowship for Interdisciplinary Research for her work on developing new techniques and algorithms for the acquisition, reconstruction and quantitative analysis of Magnetic Resonance Spectroscopy Imaging (MRSI), with the goal of improving its speed, sensitivity and specificity to improve the management of patients with brain tumors. She conducted her post-doctoral fellowship at UCSF, combining structural, physiological and metabolic imaging data from large clinical trials to quantitatively characterize heterogeneity within malignant brain tumors.